Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects associated with AD psychosis, as […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!